100k shorts yesterday on trading a little over 300k at a guess (280k ASX plus ? Cboe)
They have $30m cash so there's no financial stress from any likely CR, so I guess the issue is
The FDA has reviewed AROA’s 510(k) application for Myriad Flow™, a new soft tissue
regeneration product that could be commercialised in combination with Enivo™, and requested
additional pre-clinical and clinical data to support a clearance. Both studies appear to be less
complex than anticipated with regulatory clearances expected within 24 months.
and
AROA is updating its FY24 full-year guidance for total revenue, product revenue, product gross margin
and a normalised EBITDA loss to NZ$67-70 million, NZ$66-69 million, 85% and NZ$1-3 million
respectively.2 Previous guidance (published on 28 November 2023) was in the range of NZ$73-76
million, NZ$72-75 million, 85% and NZ$1-2 million [profit]
Slippage! A 12 month delay to profitability.
Come on finish 1.60 plus, page-437
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
-0.065(12.9%) |
Mkt cap ! $151.4M | |||
| Open | High | Low | Value | Volume |
| 50.0¢ | 50.0¢ | 44.0¢ | $2.259M | 4.988M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12699 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 1954 | 1 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| ARX (ASX) Chart |